IROX as second-line therapy for metastatic colorectal cancer

被引：0
|
作者：
Alberto Sobrero
机构：
[1] Ospedale San Martino,
来源：
Nature Reviews Clinical Oncology | 2009年 / 6卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Haller et al. demonstrated that irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoropyrimidine failure in advanced colorectal cancer. IROX does not change, but enriches the treatment algorithm of advanced colorectal cancer at the second-line level.
引用
收藏
页码：248 / 250
页数：2
相关论文
共 50 条
  • [21] Phase I Study of Everolimus, Cetuximab and Irinotecan as Second-line Therapy in Metastatic Colorectal Cancer
    Hecht, J. Randolph
    Reid, Tony R.
    Garrett, Christopher R.
    Beck, J. Thaddeus
    Davidson, Sheldon J.
    Mackenzie, Mary J.
    Brandt, Ulrike
    Rizvi, Syed
    Sharma, Sunil
    ANTICANCER RESEARCH, 2015, 35 (03) : 1567 - 1573
  • [22] Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer
    Ursina R. Teitelbaum
    Daniel G. Haller
    Nature Reviews Clinical Oncology, 2009, 6 : 250 - 251
  • [23] Metastatic colorectal cancer:: First- and second-line treatment in 2005
    Rougier, P
    Lepère, C
    SEMINARS IN ONCOLOGY, 2005, 32 (06) : S15 - S20
  • [24] Raltitrexed plus oxaliplatin in the second-line treatment of metastatic colorectal cancer
    Vyzula, R
    Kocáková, I
    Demlová, R
    Kiss, I
    Dusek, L
    Jarkovsky, J
    NEOPLASMA, 2006, 53 (02) : 119 - 127
  • [25] Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer
    Teitelbaum, Ursina R.
    Haller, Daniel G.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (05) : 250 - 251
  • [26] Efficacy and safety of cetuximab plus FOLFOX in second-line and third-line therapy in metastatic colorectal cancer
    Ozaslan, Ersin
    Topaloglu, Ulas Serkan
    Inanc, Mevlude
    Erdem, Umut Gokmen
    Demir, Hacer
    Arpaci, Erkan
    Seker, Mehmet Metin
    Karaaga, Mustafa
    Kiziltepe, Melih
    Eker, Baki
    Ozkan, Metin
    JOURNAL OF BUON, 2017, 22 (04): : 863 - 868
  • [27] Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer
    Fuchs, CS
    Moore, MR
    Harker, G
    Villa, L
    Rinaldi, D
    Hecht, JR
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (05) : 807 - 814
  • [28] Efficacy and safety of CapeIRI plus bevacizumab therapy as a second-line treatment for patients with metastatic colorectal cancer
    Sunagawa, Y.
    Nakayama, G.
    Hattori, N.
    Ezaka, K.
    Uda, H.
    Umeda, S.
    Sato, B.
    Yamada, S.
    Sugimito, H.
    Koike, M.
    Kodera, Y.
    ANNALS OF ONCOLOGY, 2017, 28
  • [29] Optimizing the Treatment Sequence From Second-Line to Third-Line Therapy in Patients With Metastatic Colorectal Cancer: Discussion
    Grothey, Axel
    Prager, Gerald W.
    Yoshino, Takayuki
    Bekaii-Saab, Tanios S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (01) : 21 - 23
  • [30] Continuing bevacizumab with second-line chemotherapy for metastatic colorectal cancer prolongs survival
    不详
    COLORECTAL CANCER, 2012, 1 (04) : 281 - 282
12345